Studies, such as those from the Danish Breast Cancer Group, have shown that recurrences can continue up to 32 years after primary treatment, especially in patients with larger tumor sizes, positive lymph nodes, and ER+ tumors [5,13]. This evidence concerns the gene ESR1 and breast carcinoma.